Terminated PHASE3 INTERVENTIONAL NCT00626600

A Study to Assess the Safety and Tolerability of Oxycodone Hydrochloride 50mg/mL Administered as an Infusion

An Open, Multi-centre, Non-comparative Observational Study to Assess the Safety and Tolerability of Oxycodone Injection 50 mg/mL as a Subcutaneous Infusion in Patients With Severe Cancer Pain.

Sponsor: Mundipharma Research Limited

Conditions Severe Caner Pain

Interventions Oxycodone Hydrochloride

Updated 6 times since 2017 Last updated: Oct 22, 2018 Started: May 31, 2008 Primary completion: May 31, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of recruitment

Other terminated trials from Mundipharma Research Limited

More terminations from Mundipharma Research Limited

Listed as NCT00626600, this PHASE3 trial focuses on Severe Caner Pain and remains terminated or withdrawn. Sponsored by Mundipharma Research Limited, it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Nov 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Nov 2018 [monthly]

Terminated PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mundipharma Research Limited

Data source: Mundipharma Research Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom